Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Huub Schellekens

Showing results (11-20 of 122) with videos related to

Pageof 13
Sort By:
Best Practice & Research. Clinical Haematology|March 29, 2005
Immunologic mechanisms of EPO-associated pure red cell aplasiaHuub Schellekens
Nature Reviews. Drug Discovery|July 18, 2002
Bioequivalence and the immunogenicity of biopharmaceuticalsHuub Schellekens
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|June 17, 2003
Immunogenicity of therapeutic proteinsHuub Schellekens
Discovery Medicine|July 1, 2010
The immunogenicity of therapeutic proteinsHuub Schellekens
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|April 14, 2005
Follow-on biologics: challenges of the "next generation"Huub Schellekens
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|June 17, 2005
Factors influencing the immunogenicity of therapeutic proteinsHuub Schellekens
Nederlands Tijdschrift Voor Geneeskunde|December 13, 2012
[Overregulation and unnecessary animal testing: requirements for market approval of biopharmaceuticals too rigid]Huub Schellekens
Kidney & Blood Pressure Research|September 15, 2007
Lesson learned from Eprex-associated pure red cell aplasiaHuub Schellekens
Nature Biotechnology|January 12, 2010
Clinical comparability and European biosimilar regulationsHuub Schellekens, Ellen Moors
Current Opinion in Biotechnology|November 7, 2009
B-1 cells and naturally occurring antibodies: influencing the immunogenicity of recombinant human therapeutic proteins?Melody Sauerborn, Huub Schellekens
Pageof 13

Showing results (11-20 of 122) with videos related to

Sort By:
Pageof 13
Best Practice & Research. Clinical Haematology|March 29, 2005
Immunologic mechanisms of EPO-associated pure red cell aplasiaHuub Schellekens
Nature Reviews. Drug Discovery|July 18, 2002
Bioequivalence and the immunogenicity of biopharmaceuticalsHuub Schellekens
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|June 17, 2003
Immunogenicity of therapeutic proteinsHuub Schellekens
Discovery Medicine|July 1, 2010
The immunogenicity of therapeutic proteinsHuub Schellekens
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|April 14, 2005
Follow-on biologics: challenges of the "next generation"Huub Schellekens
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|June 17, 2005
Factors influencing the immunogenicity of therapeutic proteinsHuub Schellekens
Nederlands Tijdschrift Voor Geneeskunde|December 13, 2012
[Overregulation and unnecessary animal testing: requirements for market approval of biopharmaceuticals too rigid]Huub Schellekens
Kidney & Blood Pressure Research|September 15, 2007
Lesson learned from Eprex-associated pure red cell aplasiaHuub Schellekens
Nature Biotechnology|January 12, 2010
Clinical comparability and European biosimilar regulationsHuub Schellekens, Ellen Moors
Current Opinion in Biotechnology|November 7, 2009
B-1 cells and naturally occurring antibodies: influencing the immunogenicity of recombinant human therapeutic proteins?Melody Sauerborn, Huub Schellekens
Pageof 13